GPR79: A Protein Potential Drug Target and Biomarker for Neurological Disorders

Target Name: GPR79

NCBI ID: G27200

GPR79

Other Name(s): GPR79P | PFI-020 | G protein-coupled receptor 79, pseudogene | G protein-coupled receptor 79 pseudogene

GPR79: A Protein Potential Drug Target and Biomarker for Neurological Disorders

GPR79 (also known as GPR79P) is a protein that is expressed in many tissues throughout the body. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. GPR79 is primarily expressed in the brain and nervous system, and it is involved in a number of different signaling pathways.

One of the most promising aspects of GPR79 is its potential as a drug target. GPR79 has been shown to play a role in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, GPR79 has also been implicated in a number of other neurological conditions, including epilepsy, depression, and anxiety.

GPR79 is also a potential biomarker for these conditions. By measuring the levels of GPR79 in brain tissue or fluids, researchers may be able to diagnose or monitor the progress of these conditions. This could be a valuable tool for early disease detection and treatment.

In addition to its potential drug and biomarker applications, GPR79 is also of interest to researchers because of its unique structure and biology. GPR79 is a small protein that is expressed in many different tissues throughout the body. Its unique shape and the way it interacts with other proteins in the body are still not fully understood.

One of the most interesting aspects of GPR79's biology is its role in neural development and plasticity. GPR79 is expressed in the neural stem cells that give rise to all of the different types of neurons in the brain. It is also involved in the formation of new neural connections and the regulation of synaptic plasticity.

GPR79's role in neural development and plasticity is still not fully understood, but it is clear that it plays an important role. Studies have shown that GPR79 is involved in the development and maintenance of neural stem cells, and that it plays a role in the formation of new neural connections.

In addition to its role in neural development and plasticity, GPR79 is also of interest to researchers because of its potential as a drug target. Its unique structure and biology make it an attractive target for small molecule inhibitors, which could be used to treat a variety of neurodegenerative diseases.

GPR79 is also of interest to researchers because of its potential as a biomarker for a variety of neurological conditions. Its expression in many different tissues throughout the body makes it a potential target for diagnostic tests, and its involvement in a number of different signaling pathways makes it a potential target for the treatment of a variety of neurological conditions.

In conclusion, GPR79 is a protein that is expressed in many tissues throughout the body and is involved in a number of different signaling pathways. Its unique structure and biology make it an attractive target for small molecule inhibitors, and its potential as a drug and biomarker for a variety of neurological conditions makes it a promising target for research into the treatment of these conditions. Further research is needed to fully understand the role of GPR79 in neural development and plasticity, and to determine its potential as a drug.

Protein Name: G Protein-coupled Receptor 79, Pseudogene

The "GPR79 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR79 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets